PUBLIC COMPANY
saveAMGEN
USupdated 4mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
- phase4A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
- phase3A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
- phase1Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
- phase3A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- phase3Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
- phase4A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
- phase3A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
🐶 Hiring Signal
News
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 2d ago
- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerNovartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager that showed early clinical promise in autoimmune disease. The deal, which includes up to $7.2 billion i…fiercebiotech · 3d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 3d ago
- Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshakenThe revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to di…fiercebiotech · 3d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 4d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 4d ago
- Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibodyAmgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.fiercebiotech · 5d ago
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.biopharma_dive · 6d ago
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealDaiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.fiercebiotech · 7d ago
comments(0)
5-min edit window · permanent after that